NASDAQ: IFRX
Inflarx Nv Stock Forecast, Predictions & Price Target

Analyst price target for IFRX

Based on 1 analyst offering 12 month price targets for Inflarx Nv

Min Forecast
$8.00+207.69%
Avg Forecast
$8.00+207.69%
Max Forecast
$8.00+207.69%

Should I buy or sell IFRX stock?

Based on 1 analyst offering ratings for Inflarx Nv.

Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although IFRX's forecast from analysts indicates a "Buy", our proven Zen Rating quant model rates IFRX as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +7.53% per year. Learn More

Be the first to know when Wall Street analysts revise their IFRX stock forecasts and price targets.

IFRX stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-01-16

1 of 1

Forecast return on equity

Is IFRX forecast to generate an efficient return?

Company
84.72%
Industry
239.02%
Market
89.33%
IFRX's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is IFRX forecast to generate an efficient return on assets?

Company
69.41%
Industry
34.72%
IFRX is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

IFRX earnings per share forecast

What is IFRX's earnings per share in the next 3 years based on estimates from 3 analysts?

Avg 1 year Forecast
-$1.16
Avg 2 year Forecast
-$0.79
Avg 3 year Forecast
$0.24

IFRX revenue forecast

What is IFRX's revenue in the next 3 years based on estimates from 2 analysts?

Avg 1 year Forecast
$1.5M+722.56%
Avg 2 year Forecast
$50.0M+26,617.09%
Avg 3 year Forecast
$168.4M+89,820.47%
IFRX's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

IFRX revenue growth forecast

How is IFRX forecast to perform vs Biotechnology companies and vs the US market?

Company
835.62%
Industry
49.49%
Market
11.68%
IFRX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
IFRX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

IFRX vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
IFRX$2.60$8.00+207.69%Buy
CDTX$21.73$32.20+48.18%Strong Buy
LXEO$4.62$22.75+392.42%Strong Buy
ADAP$0.60$2.67+343.76%Strong Buy
LYEL$0.55$1.00+80.83%Sell

Inflarx Nv Stock Forecast FAQ

Is Inflarx Nv Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: IFRX) stock is to Buy IFRX stock.

Out of 1 analyst, 0 (0%) are recommending IFRX as a Strong Buy, 1 (100%) are recommending IFRX as a Buy, 0 (0%) are recommending IFRX as a Hold, 0 (0%) are recommending IFRX as a Sell, and 0 (0%) are recommending IFRX as a Strong Sell.

If you're new to stock investing, here's how to buy Inflarx Nv stock.

What is IFRX's earnings growth forecast for 2025-2027?

(NASDAQ: IFRX) Inflarx Nv's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 14.38%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 19.63%.

Inflarx Nv's earnings in 2025 is -$61,164,287.On average, 3 Wall Street analysts forecast IFRX's earnings for 2025 to be -$68,304,596, with the lowest IFRX earnings forecast at -$77,137,086, and the highest IFRX earnings forecast at -$59,472,105. On average, 3 Wall Street analysts forecast IFRX's earnings for 2026 to be -$46,712,100, with the lowest IFRX earnings forecast at -$66,538,097, and the highest IFRX earnings forecast at -$18,842,647.

In 2027, IFRX is forecast to generate $14,131,985 in earnings, with the lowest earnings forecast at $14,131,985 and the highest earnings forecast at $14,131,985.

What is IFRX's revenue growth forecast for 2025-2027?

(NASDAQ: IFRX) Inflarx Nv's forecast annual revenue growth rate of 835.62% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 49.49%, and it is also forecast to beat the US market's average forecast revenue growth rate of 11.68%.

Inflarx Nv's revenue in 2025 is $181,181.On average, 2 Wall Street analysts forecast IFRX's revenue for 2025 to be $90,680,239, with the lowest IFRX revenue forecast at $60,060,937, and the highest IFRX revenue forecast at $121,299,540. On average, 2 Wall Street analysts forecast IFRX's revenue for 2026 to be $2,945,341,265, with the lowest IFRX revenue forecast at $128,954,366, and the highest IFRX revenue forecast at $5,761,728,165.

In 2027, IFRX is forecast to generate $9,912,998,841 in revenue, with the lowest revenue forecast at $9,912,998,841 and the highest revenue forecast at $9,912,998,841.

What is IFRX's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: IFRX) forecast ROA is 69.41%, which is higher than the forecast US Biotechnology industry average of 34.72%.

What is IFRX's Price Target?

According to 1 Wall Street analyst that have issued a 1 year IFRX price target, the average IFRX price target is $8.00, with the highest IFRX stock price forecast at $8.00 and the lowest IFRX stock price forecast at $8.00.

The Wall Street analyst predicted that Inflarx Nv's share price could reach $8.00 by Jan 16, 2026. The average Inflarx Nv stock price prediction forecasts a potential upside of 207.69% from the current IFRX share price of $2.60.

What is IFRX's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: IFRX) Inflarx Nv's current Earnings Per Share (EPS) is -$1.07. On average, analysts forecast that IFRX's EPS will be -$1.16 for 2025, with the lowest EPS forecast at -$1.31, and the highest EPS forecast at -$1.01. On average, analysts forecast that IFRX's EPS will be -$0.79 for 2026, with the lowest EPS forecast at -$1.13, and the highest EPS forecast at -$0.32. In 2027, IFRX's EPS is forecast to hit $0.24 (min: $0.24, max: $0.24).

What is IFRX's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: IFRX) forecast ROE is 84.72%, which is considered strong.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.